Botulinum Toxin Type a in the Treatment of Sialorrhea in Parkinson's Disease

Drooling in Parkinson's disease: A review

“…Seven studies including 1 case series [53], 3 open-label studies [54,55,56], 1 open-labelled case-control study [57], 1 randomized placebo-control study [58] and 1 randomized, double-blinded, placebo-control study [59] used onabotulinumtoxinA for treating drooling patients with PD. OnabotulinumtoxinA was injected into the parotid glands for all studies.…”

“…No studies compared injection of the parotid glands with the submandibular glands. Five studies used a blind injection technique [53,54,55,57,59] whereas 2 studies used ultrasound guidance [56,58]. Santamato et al conducted an open-label study using ultrasound-guided toxin injection in 18 drooling PD patients while Dogu et al conducted a randomized control study comparing toxin injection in 15 drooling PD patients divided into arms using (n=8) and not-using (n=7) ultrasound guidance.…”

“…Santamato et al conducted an open-label study using ultrasound-guided toxin injection in 18 drooling PD patients while Dogu et al conducted a randomized control study comparing toxin injection in 15 drooling PD patients divided into arms using (n=8) and not-using (n=7) ultrasound guidance. In terms of pre- and post-treatment evaluation, 2 studies only used subjective assessment [53,56], 1 only used objective assessment [57], and 4 used both subjective and objective assessment [54,55,58,59]. The subjective assessment tools included reporting from patients and their spouses, DSFS and VAS for drooling severity, frequency, VASFS and VAS-SD.…”

Botulinum Toxin Type a in the Treatment of Sialorrhea in Parkinson's Disease

“…To the Editor: We read with great interest the article “Botulinum toxin type A in the treatment of sialorrhea in Parkinson's disease” by Santamato et al 1 in the Journal of the American Geriatrics Society , and we would like to raise some points. First, we congratulate the Journal for the interest in the topic, which is related to prognosis and quality of life of patients with Parkinson's disease (PD), but we also must express our surprise, because the article has many similarities to our recent publication “Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?” 2 Although without citation, it was nice to see that the authors followed a similar protocol to ours to investigate the role of botulinum toxin type A (BTX‐A) to treat sialorrhea in patients with PD.…”

Effectiveness of botulinum toxin type A treatment of neck pain related to nocturnal bruxism: a case report

“…Recent reports have indicated that BTX-A is safe and effective in the treatment of neuromuscular disorders such as focal, segmental dystonia (torticollis, oromandibular dystonia, laryngeal dystonia, writer's cramp); hemifacial spasm 1 ; and hypersecretory disorders such as hyperhidrosis and sialorrhea. [2][3][4] Botulinum toxin type A injected into the skeletal muscle belly prevents the release of acetylcholine from the presynaptic axon of the motor endplate and blocks signal transmission at the neuromuscular junction. This process reduces muscle contraction, inducing a weakness condition.…”